Edwards Lifesciences Reports Fourth Quarter Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Canaccord Genuity Raises Price target on Edwards Lifesciences (EW) as TAVI Continues to Grow
February 3, 2016 10:06 AM ESTCanaccord Genuity reiterated a Buy rating on Edwards Lifesciences (NYSE: EW), and raised the price target to $92.00 (from $90.00), following the company's 4Q. Checks imply growing acceptance of TAVI as a durable therapy for severe, symptomatic aortic valve disease, with predictable outcomes and consistent results rapidly... More
Edwards Lifesciences (EW) PT, Estimate Raised at Piper Jaffray on Strong 2015 Finish
February 3, 2016 7:42 AM ESTPiper Jaffray analyst Brooks West reiterated an Overweight rating and boosted his price target on Edwards Lifesciences (NYSE: EW) to $97.00 (from $90.00) following a strong finish to 2015 and higher 2016 guidance.
West commented, "Edwards reported Q4 revenues of $671.1M, beating our estimate of $647.7M and consensus $648.8M. Upside... More
Edwards Lifesciences (EW) Tops Q4 EPS by 1c; Guides Above the Street
February 2, 2016 4:17 PM ESTEdwards Lifesciences (NYSE: EW) reported Q4 EPS of $0.63, $0.01 better than the analyst estimate of $0.62. Revenue for the quarter came in at $671.1 million versus the consensus estimate of $648.74 million.
GUIDANCE:
Edwards Lifesciences sees FY2016 EPS of $2.57-$2.67, versus the consensus... More
